Fireman B.V. IFRX

$1.72 -0.02 (-0.87%)

Valuation

Market cap
254,947,000
Revenue TTM
$30,000
Net income TTM
$-51,630,000
PE ratio
0.00
Forward PE
—
Profit margin
-172,100.01%
Debt to equity
0.00

Trading

Volume
306,500
Avg volume
704,536
Day's range
$1.71 – $1.79
Shares out
147,368,000
Stochastic %K
85%
Beta
2.59
Analysts
Strong Sell
Price target
$8.25

Price

Company profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the trea...

Show more

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Industry
Biotechnology
Sector
Healthcare
Phone
49 3641 508 180
Website
https://www.inflarx.de
Address
Winzerlaer Str. 2, Jena, Germany

Latest news

Stocktwits

MrCompassion Oct 30, 1:28 PM
$IFRX I happened across these links but can’t find direct links to them from the InflaRx website (assuming that work is still in progress). Looks like a newly assembled renal/AAV expert group that hasn’t been announced yet. https://www.inflarx.de/Home/About-Inflarx/Team~Professor-Jonathan-Barratt--PhD--FRCP~.html https://www.inflarx.de/Home/About-Inflarx/Team~J-rgen-Floege~.html https://www.inflarx.de/Home/About-Inflarx/Team~Prof.-Dr.-med.-Bernhard-Hellmich~.html https://www.inflarx.de/Home/About-Inflarx/Team~David-Jayne--MD--FMedSci~.html https://www.inflarx.de/Home/About-Inflarx/Team~Andreas-Kronbichler~.html https://www.inflarx.de/Home/About-Inflarx/Team~Peter-A.-Merkel--MD--MPH~.html https://www.inflarx.de/Home/About-Inflarx/Team~Dr.-Ming-hui-ZHAO~.html All seven are renal or AAV. Five are nephrologists and two are vasculitis rheumatologists. Nobody comes from derm, HS, PG or critical care. What the composition says - It’s a guideline-writing group. Between them they hold KDIGO glomerular disease (Floege coordinating, Barratt on IgAN), EULAR AAV (Hellmich, writing the 2027 version) and EUVAS (Jayne). Positioning izicopan in the 2027 EULAR AAV update, after the Tavneos EU revocation, is a credible near-term aim. - It covers regulatory endpoints. Barratt worked on validating proteinuria as a
4 replies
MrCompassion Oct 30, 12:58 PM
$IFRX "InflaRx Co-Founder and CEO Niels Riedemann discusses the company’s upcoming Virtual Capital Markets Day" https://x.com/HCWCO/status/2115877931507392887
0 replies
FlowerInTheCellar Oct 30, 11:45 AM
$IFRX IgAN: The Gut–Kidney Axis and the Complement System A new AJKD Core Curriculum 2026, published on October 29, highlights the role of intestinal mucosal immunity in IgA nephropathy. Dysregulation of the immune system in the gut can promote the production of galactose-deficient IgA1 (Gd-IgA1). The resulting immune complexes can accumulate in the kidneys and trigger inflammation. Relevance to IFRX: This provides interesting scientific background for InflaRx’s planned IgAN program. While the dysregulated IgA immune response is an early step in the disease process, izicopan targets a downstream inflammatory mechanism by blocking C5aR1. The article brings together different aspects of the disease biology, but provides no new clinical efficacy data for izicopan. *Please verify the sources and content independently.
0 replies
Monkey82 Oct 30, 5:09 AM
$IFRX A good read. Permission to access is required from the author. https://x.com/giger1964/status/2105660820948447726?s=46
0 replies
Yoyo35 Oct 29, 8:11 PM
$IFRX
2 replies
SeriousDan Oct 29, 12:17 PM
1/3 $IFRX CMD Nov 3: what could a best-case AAV design look like? My read of Niels' recent talks (my interpretation, not company guidance). Study: randomized, controlled Ph2b, ideally with blinded BVAS adjudication, first sites early 2027. BVAS is partly subjective (residual symptoms after 3 months), so blinding/adjudication matters a lot for credibility. Primary endpoint: BVAS 0 remission (wk 26) as NON-INFERIORITY vs standard of care. Why: sustained remission at wk 52 can't exceed the wk 26 rate (~70%). Control ~60% vs an ideal drug ~70% = 10 pts max. By his math that needs ~1,000 pts for superiority. NI with an FDA-accepted margin is far smaller.
1 replies
_KREAMER Oct 29, 12:06 PM
This guy called AIOK and it went parabolic! He's been on fire Make sure to give @GladiatorPicks a Follow. Actually a decent trader 🔥💯 $CLRB $SRPT $IFRX $NKE Great dip buys here
0 replies
NYBomba Oct 28, 9:40 PM
$IFRX - sweet chart and OBV rise ...☮️
0 replies